Drug Type Synthetic peptide |
Synonyms PRI-100 |
Target |
Action inhibitors |
Mechanism α-synuclein inhibitors(Synuclein alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Parkinson Disease | Preclinical | Germany | 30 Jan 2022 |






